RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease

Dimitry Ofengeim,Sonia Mazzitelli,Yasushi Ito,Judy Park DeWitt,Lauren Mifflin,Chengyu Zou,Sudeshna Das,Xian Adiconis,Hongbo Chen,Hong Zhu,Michelle A. Kelliher,Joshua Z. Levin,Junying Yuan
DOI: https://doi.org/10.1073/pnas.1714175114
IF: 11.1
2017-09-13
Proceedings of the National Academy of Sciences
Abstract:Significance Dysfunction of microglia plays a fundamental role in the pathogenesis of Alzheimer’s disease (AD), the most common form of dementia. However, there is a lack of knowledge about targets that can be safely manipulated for modulating microglia for the treatment of AD. The presence of a unique subtype of disease-associated microglia (DAM) has recently been implicated in mediating pathogenesis of AD. However, the mechanism that promotes the development of DAM is unclear, nor is it known how DAM may modulate the progression of AD. This study demonstrates that RIPK1-dependent transcription promotes DAM and lysosomal defects to mediate the accumulation of amyloid plaques in AD. Thus, targeting RIPK1 may provide an important therapeutic strategy for the treatment of AD.
What problem does this paper attempt to address?